Found: 167
Select item for more details and to access through your institution.
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective.
- Published in:
- 2016
- By:
- Publication type:
- journal article
High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma.
- Published in:
- British Journal of Haematology, 1999, v. 107, n. 1, p. 121, doi. 10.1046/j.1365-2141.1999.01685.x
- By:
- Publication type:
- Article
A Review of the Main Driving Factors of Forest Fire Ignition Over Europe.
- Published in:
- Environmental Management, 2013, v. 51, n. 3, p. 651, doi. 10.1007/s00267-012-9961-z
- By:
- Publication type:
- Article
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01089-5
- By:
- Publication type:
- Article
Evaluation of CMIP6 model performances in simulating fire weather spatiotemporal variability on global and regional scales.
- Published in:
- Geoscientific Model Development, 2023, v. 16, n. 10, p. 3103, doi. 10.5194/gmd-16-3103-2023
- By:
- Publication type:
- Article
Measurable residual disease in multiple myeloma: ready for clinical practice?
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00911-4
- By:
- Publication type:
- Article
11 C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18 F-FDG PET/CT and Prognostic Value.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 17, p. 9895, doi. 10.3390/ijms23179895
- By:
- Publication type:
- Article
ERA5-based global meteorological wildfire danger maps.
- Published in:
- Scientific Data, 2020, v. 7, n. 1, p. 1, doi. 10.1038/s41597-020-0554-z
- By:
- Publication type:
- Article
A global wildfire dataset for the analysis of fire regimes and fire behaviour.
- Published in:
- Scientific Data, 2019, v. 6, n. 1, p. N.PAG, doi. 10.1038/s41597-019-0312-2
- By:
- Publication type:
- Article
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1197340
- By:
- Publication type:
- Article
Influence of antiplatelet-anticoagulant drugs on the need of blood components transfusion after vesical transurethral resection.
- Published in:
- Archives of Italian Urology & Andrology / Archivio Italiano di Urologia Andrologia, 2015, v. 87, n. 2, p. 136, doi. 10.4081/aiua.2015.2.136
- By:
- Publication type:
- Article
Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. e48, doi. 10.1111/bjh.17448
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
- By:
- Publication type:
- Article
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 522, doi. 10.1111/bjh.16788
- By:
- Publication type:
- Article
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure–response analysis.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 860, doi. 10.1111/bjh.16446
- By:
- Publication type:
- Article
Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 5, p. e117, doi. 10.1111/bjh.15946
- By:
- Publication type:
- Article
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 66, doi. 10.1111/bjh.14821
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 896, doi. 10.1111/bjh.14787
- By:
- Publication type:
- Article
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 4, p. 547, doi. 10.1111/bjh.14708
- By:
- Publication type:
- Article
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 3, p. 404, doi. 10.1111/bjh.14549
- By:
- Publication type:
- Article
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 3, p. 448, doi. 10.1111/bjh.14263
- By:
- Publication type:
- Article
Phase I/II study of weekly PM00104 (Zalypsis<sup>®</sup>) in patients with relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 4, p. 625, doi. 10.1111/bjh.13515
- By:
- Publication type:
- Article
A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 6, p. 804, doi. 10.1111/bjh.13500
- By:
- Publication type:
- Article
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen ( RIC) and post-allogeneic transplantation for high-risk myeloma patients.
- Published in:
- British Journal of Haematology, 2013, v. 162, n. 4, p. 474, doi. 10.1111/bjh.12410
- By:
- Publication type:
- Article
Forest fires and adaptation options in Europe.
- Published in:
- Regional Environmental Change, 2016, v. 16, n. 1, p. 21, doi. 10.1007/s10113-014-0621-0
- By:
- Publication type:
- Article
Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. 700, doi. 10.1002/ajh.26507
- By:
- Publication type:
- Article
Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 3, p. E113, doi. 10.1002/ajh.26450
- By:
- Publication type:
- Article
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 896, doi. 10.1002/ajh.26263
- By:
- Publication type:
- Article
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network.
- Published in:
- Kompass Onkologie, 2022, v. 9, n. 1, p. 3, doi. 10.1159/000522451
- By:
- Publication type:
- Article
Interpretation klinischer Studiendaten zum Multiplen Myelom: Übertragung der Ergebnisse auf die klinische Praxis.
- Published in:
- Kompass Onkologie, 2019, v. 6, n. 1, p. 10, doi. 10.1159/000497022
- By:
- Publication type:
- Article
Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0121581
- By:
- Publication type:
- Article
Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis.
- Published in:
- PLoS ONE, 2015, v. 10, n. 1, p. 1, doi. 10.1371/journal.pone.0116966
- By:
- Publication type:
- Article
Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138<sup>++</sup> and CD138<sup>low</sup> Subpopulations in Multiple Myeloma Cell Lines.
- Published in:
- PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0092378
- By:
- Publication type:
- Article
Immunologic monitoring in adults with acute lymphoblastic leukemia.
- Published in:
- Current Oncology Reports, 2003, v. 5, n. 5, p. 413, doi. 10.1007/s11912-003-0028-4
- By:
- Publication type:
- Article
The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
- Published in:
- Annals of Hematology, 2013, v. 92, n. 1, p. 97, doi. 10.1007/s00277-012-1566-3
- By:
- Publication type:
- Article
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
- Published in:
- Annals of Hematology, 2012, v. 91, n. 12, p. 1887, doi. 10.1007/s00277-012-1538-7
- By:
- Publication type:
- Article
Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 1996, v. 60, n. 3, p. 332, doi. 10.1016/S0009-9236(97)90148-X
- By:
- Publication type:
- Article
Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora's Box of Multiple Myeloma.
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1430, doi. 10.3390/cancers14061430
- By:
- Publication type:
- Article
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4924, doi. 10.3390/cancers13194924
- By:
- Publication type:
- Article
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial.
- Published in:
- Cancers, 2020, v. 12, n. 12, p. 3615, doi. 10.3390/cancers12123615
- By:
- Publication type:
- Article
18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers.
- Published in:
- Cancers, 2020, v. 12, n. 4, p. 1042, doi. 10.3390/cancers12041042
- By:
- Publication type:
- Article
Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 6, p. 352
- By:
- Publication type:
- Article
Molecular Characterization of Complete and Incomplete Immunoglobulin Heavy Chain Gene Rearrangements in Hairy Cell Leukemia.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 7, n. 9, p. 573
- By:
- Publication type:
- Article
Prognostic Impact of Pretransplantation Computed Tomography and Gallium Scans in Patients with Hodgkin Lymphoma with Poor Prognosis Undergoing Hematopoietic Stem Cell Transplantation.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 7, n. 3, p. 217
- By:
- Publication type:
- Article
The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
- Published in:
- 2002
- By:
- Publication type:
- journal article
RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 1, p. 200, doi. 10.1007/s10637-012-9845-3
- By:
- Publication type:
- Article
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 3, p. 1121, doi. 10.1007/s10637-011-9670-0
- By:
- Publication type:
- Article
The DAC system and associations with multiple myeloma.
- Published in:
- Investigational New Drugs, 2010, v. 28, p. 28, doi. 10.1007/s10637-010-9589-x
- By:
- Publication type:
- Article
Towards an Integrated Approach to Wildfire Risk Assessment: When, Where, What and How May the Landscapes Burn.
- Published in:
- Fire (2571-6255), 2023, v. 6, n. 5, p. 215, doi. 10.3390/fire6050215
- By:
- Publication type:
- Article